New Lupus Drug Benlysta Offers Long-Awaited Hope
WASHINGTON (CBSNewYork.com/AP) The Food and Drug Administration on Wednesday approved the first new drug to treat lupus in over 50 years, a milestone that medical experts say could prompt development of other drugs that are even more effective in treating the debilitating immune system disorder.
While the exact number of patients who suffer from Lupus in the tri-state region is currently being calculated, the companies estimate there are at least 200,000 lupus patients in the U.S. who could benefit from the drug.
Known as Benlysta, the injectable drug is designed to relieve flare-ups and pain caused by lupus, a little-understood and potentially fatal ailment in which the body attacks its own tissue and organs.
“I’ve been waiting for this day since I was diagnosed with lupus more than 40 years ago,” said Susan Golick, co-founder of the S.L.E. Lupus Foundation. “When my father Morrie and I started this organization in 1970, lupus was often a death sentence. We made it our mission to be a motivating force to the patient and medical communities, working to improve the lives of people with lupus while fighting for a cure. It’s been a long and frustrating journey, but we haven’t given up, and now we can be confident that industry and scientists aren’t giving up either. This is the start of a new era.”
But experts stress that Benlysta is not a miracle drug: It only worked in 35 percent of North American patients tested and was not effective for patients with the deadliest form of the disease. Additionally, it did not show positive results in African Americans, who are disproportionately affected by lupus.
FDA said in its news release it would require the drug developers to conduct another study exclusively in African Americans.
Dr. Betty Diamond, who has studied lupus for 30 years, said Benlysta should provide encouragement to researchers and drug developers.
‘It will send out the message that it’s possible to conduct a successful clinical trial in lupus and that’s tremendously important to keep the pharmaceutical industry interested in this disease,” said Diamond, a researcher at the Feinstein Institute in New York.
Janice Fitzgibbon of McLean, Virginia has been taking Benlysta for two years as part of the drug’s clinical trial program.
“It’s given me my life back,” she said, after being so crushed by pain that she couldn’t take her dog for a walk or drive her children to school.
“It’s a bittersweet thing for me because I have friends with lupus for whom this drug won’t work,” said Fitzgibbon, who is 54. “There’s no one-size-fits-all for lupus and I’m just extremely fortunate that my lupus is mild and is helped by Benlysta.”
“After decades of suffering from harsh drugs with devastating side effects, people with lupus now have real options for safer and more effective treatments,” added the Foundation’s Executive Director Margaret Dowd. “This is a huge step forward for the lupus community and a victory for the 1.5 million Americans who struggle with lupus daily. Now we can stop looking back on the dearth of treatments over the past decades, and look forward to new research and accelerated drug development that will give us myriad therapies, more precise care, and a cure.”
FDA approved the drug for systemic lupus erythematosus, the most common form of the disease. Ten-year survival for patients diagnosed with the illness is more than 85 percent, according to the National Institutes of Health.
Lupus patients have long struggled to draw attention to their disease, which affects women nine times more than men. African Americans are three times more likely to have the disease.
“I don’t think there’s a conspiracy here, but it just hasn’t gotten a lot of funding and it hasn’t gotten a lot of attention from the media,” said Dr. Abby Abelson, chair of the Department of Rheumatologic and Immunologic Disease at the Cleveland Clinic.
Lupus causes fibrous tissue and inflammation of internal organs, skin rashes and joint pain. Most of Benlysta’s benefit came from relieving muscle inflammation versus organ problems, as measured on a comprehensive checklist of lupus symptoms.
The disease occurs when the body’s protector cells, known as antibodies, stop differentiating between foreign invaders, like bacteria, and healthy cells. The cause of this malfunction is not understood.
Currently most patients treat their disease with a variety of drugs that help ease inflammation, including painkillers, steroids and antimalarial drugs which were first approved for lupus in the1950s. Many patients say the side effects of those treatments are nearly as uncomfortable as the disease itself. Steroids can cause bone fractures, weight gain and infection.
“The wait is over, and the lupus community can now rejoice over today’s historic approval, which marks a major milestone in lupus research and treatment,” said Richard Furie, MD, chief of the division of rheumatology and allergy-clinical rheumatology at North Shore-LIJ Health System in New York. “Not only does this approval add a new medication to the physician’s toolbox, but it will also serve as a catalyst for yet more sorely needed drug research and development in lupus.”
Wednesday’s approval completes a remarkable turnaround for Rockville, Md.,-based Human Genome Sciences which has been developing Benlysta since 1996 and has no other products on the market. The company originally tested Benlysta, known generically as belimumab, as a treatment for rheumatoid arthritis.
When a mid-stage trial in lupus patients failed to meet researchers’ goals in 2006, many analysts wrote the drug off and downgraded the company’s stock. But when scientists reanalyzed the data they found that the drug helped block the antibodies that cause lupus symptoms in a subset of patients.
Analysts estimate the drug could reach annual sales exceeding $3 billion within five years.
- Benlysta approved: Which lupus patients will benefit? (cbsnews.com)